title: Protease inhibitors for treatment of genotype 1 hepatitis C virus infection.
authors.affiliation: Liver and Hepatobiliary Unit, Queen Elizabeth Hospital Birmingham, Birmingham B15 2TH, UK.
authors.forename: Ian A
authors.initials: IA
authors.lastname: Rowe
authors.forename: David J
authors.initials: DJ
authors.lastname: Mutimer
mesh_terms: D003362:Cost-Benefit Analysis; D004347:Drug Interactions; D016903:Drug Monitoring; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics*; D006526:Hepatitis C / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D009842:Oligopeptides / Q000009:adverse effects / Q000627:therapeutic use*; D011392:Proline / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
chemical_list: D009842:Oligopeptides; D011480:Protease Inhibitors; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline